

Supplementary Figure 1

Bevacizumab reduces the growth rate constants of renal carcinomas. A novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage.


Wilfred D. Stein^{1,2}

James Yang³


Susan E. Bates¹

Tito Fojo^{1,4}


Patients Randomized to Placebo




Patients Randomized to Placebo



Patients Randomized to Placebo



Patients Randomized to Placebo



Patients Randomized to Placebo

